Literature DB >> 18276839

Unique transcription start sites and distinct promoter regions differentiate the pregnane X receptor (PXR) isoforms PXR 1 and PXR 2.

Leslie M Tompkins1, Tim L Sit, Andrew D Wallace.   

Abstract

The pregnane X receptor (PXR) is known as the xenosensing receptor responsible for coordinated regulation of metabolic genes in response to diverse xenobiotic challenges. In particular, the ability of the PXR to regulate CYP3A4, the enzyme capable of metabolizing more than 60% of all pharmaceuticals, defines its metabolic importance. Currently the list of PXR ligands and target genes is extensive, yet investigations into the regulation and expression of PXRs are few. After an initial review of available sequence data, we discovered discrepancies in the 5' untranslated region (UTR) and transcriptional start site (TSS) characterizations of the human PXR gene and subsequently endeavored to define TSSs and proximal promoters for isoforms PXR 1 and PXR 2. Reverse transcriptase-polymerase chain reaction and primer extension experiments performed on RNA from human liver identified two TSSs for each receptor isoform. These results extended the 5'UTR sequence of each isoform and defined new proximal promoters for both. Candidate response elements for liver-enriched transcription factors and other receptors were found in both proximal promoters. Quantitative PCR from human liver illustrated a highly variable expression profile for total PXRs; yet PXR 2 expression represented a consistent 2 to 5% of total PXR expression, despite the observed variability. Transfection experiments demonstrated that PXR 1 and PXR 2 had comparable abilities to transcriptionally activate the CYP3A4 promoter. Collectively, comparable function, consistent expression, and independent regulation suggest that PXR 2 is capable of contributing to the cumulative function of PXRs and should be included in the larger investigations of PXR expression and regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276839     DOI: 10.1124/dmd.107.018317

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

2.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

Review 3.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

Authors:  Satyanarayana R Pondugula; Sridhar Mani
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

Review 4.  Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism.

Authors:  Tomas Smutny; Lucie Hyrsova; Albert Braeuning; Magnus Ingelman-Sundberg; Petr Pavek
Journal:  Arch Toxicol       Date:  2020-11-09       Impact factor: 5.153

5.  Suppression of the pregnane X receptor during endoplasmic reticulum stress is achieved by down-regulating hepatocyte nuclear factor-4α and up-regulating liver-enriched inhibitory protein.

Authors:  Thaveechai Vachirayonsti; Karen W Ho; Dongfang Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2015-01-22       Impact factor: 4.849

6.  Pregnane X Receptor and Cancer: Context-Specificity is Key.

Authors:  Satyanarayana R Pondugula; Petr Pavek; Sridhar Mani
Journal:  Nucl Receptor Res       Date:  2016-06-12

Review 7.  Role of pregnane X receptor in chemotherapeutic treatment.

Authors:  Wei Zhuo; Lei Hu; Jinfeng Lv; Hongbing Wang; Honghao Zhou; Lan Fan
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-03       Impact factor: 3.333

Review 8.  PXR variants: the impact on drug metabolism and therapeutic responses.

Authors:  C Trent Brewer; Taosheng Chen
Journal:  Acta Pharm Sin B       Date:  2016-07-27       Impact factor: 11.413

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.